Last deal
Amount
Stage
Date
all rounds
Total amount
date founded
Financing round
General
About Company
Industry
Sector :
Subsector :
Contacts
Similar Companies999
Acucela
Acucela Inc. is developing innovative therapeutics for sight-threatening ophthalmic diseases.
Sector
Subsector
Location
total rounds
total raised
NuVision
NuVision™ is a biotech company that develops affordable biotherapies for treating eye disease and trauma.
Sector
Subsector
Location
total rounds
total raised
Vision Genomics
Vision genomics is a biotech company that develops therapeutics for age-related eye diseases.
Sector
Subsector
Keywords
Location
total rounds
Eyevensys
Eyevensys develops a non-invasive way to deliver ophthalmic drugs to address unmet needs in ophthalmology.
Sector
Subsector
Keywords
Location
total rounds
total raised
M&A Details1
Transaction name
Acquired by
Merck Sharp & Dohme Sweden AB
announced date
price
Financials
Funding Rounds3
Number of Funding Rounds
Money Raised
Their latest funding was raised on 14.11.2023. Their latest investor Omega Funds. Their latest round Series A
Samsara BioCapital
Samsara BioCapital is a Palo Alto-based venture capital firm specializing in life sciences.
Sector
Subsector
Location
count Of Investments
count Of Exists
SV Health Investors
SV Health Investors is a leading healthcare and life sciences venture capital and growth equity firm.
Sector
Subsector
Location
count Of Investments
count Of Exists
Jeito Capital
Jeito Capital is a leading global investment company focused on financing medical innovation and promoting positive societal impact.
Sector
Subsector
Location
count Of Investments
SV Health Investors
SV Health Investors is a leading healthcare and life sciences venture capital and growth equity firm.
Sector
Subsector
Location
count Of Investments
count Of Exists
Co-Investors
Investors7
Number of lead investors
Number of investors
Omega Funds
Omega Funds is a global life sciences-based investment firm that specializes in direct secondary transactions.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
Bernard Davitian
Bernard Davitian has extensive experience in the life sciences and biotech industry, marked by a number of successful transactions involving financings and M&A. His track record includes, among others, the successful IPO of Transgene on the NASDAQ and Euronext in 1998 ($100 million raised) and the sale of Fovea Pharmaceuticals to Sanofi in 2009 in a €370 million cash transaction. Bernard joined Sanofi in 2010 as Vice President, Deputy of Global Head, Business Development Corporate Licenses and was promoted to Vice President and Managing Director of SGBV in 2012. Prior to Sanofi, Bernard was EVP & CFO of Fovea Pharmaceuticals, CEO of Neurotech Pharmaceuticals, and EVP & CFO of Transgene. Bernard began his career in the biotech sector by serving in various capacities at Institut Mérieux (now Sanofi Pasteur), including Corporate CFO. In addition to his SGBV-related Boards of Directors responsibilities, which include Immune Design, Proteostasis Therapeutics, Esperance Pharmaceuticals and Kahr Medical, Bernard also represents Sanofi on the Board of Directors of Warp Drive Bio. Bernard holds an MSc in Management from EM Lyon Business School (France). He is also a Certified Public Accountant (CPA) and holds an executive M.B.A. (AMP program) from Wharton Business School.
current job
Jeito Capital
Jeito Capital is a leading global investment company focused on financing medical innovation and promoting positive societal impact.
Sector
Subsector
Location
count Of Investments
Andreas Wallnöfer
Dr. Wallnöfer joined BioMedPartners as a new Partner in 2016. Dr. Wallnöfer is a senior executive leader with more than 20 years experience in the pharmaceutical industry, including 12 years as a member of the F. Hoffmann-La Roche Pharma R&D Leadership and Portfolio Committee. He led the Roche Pharma Cardiovascular & Metabolism Disease Area and left Roche in 2015 after the company strategically decided to exit these reasearch areas. At Roche he was involved in several successful product development programs. As Head of Clinical Research & Exploratory Development he and his groups were involved in the Due Diligence evaluations for in-licensing projects and product acquisitions. Dr. Wallnöfer had also a key role in the integration of the Roche and Genentech Development organizations and led subsequently Early Development and Portfolio Management at Roche. He will strengthen BioMed expertise in Pharma from discovery to regulatory filing submissions. Dr. Wallnöfer has a PhD in pharmacology from the University of Basel and trained as a fellow in Clinical Pharmacology at the University of Leiden, the Netherlands. He holds a Master of Technology Enterprise and an Executive MBA from IMD Lausanne.
current job
Bain Capital Life Sciences
Bain Capital Life Sciences Fund focuses on buyouts, growth capital, and private equity investments in the life sciences sector.
Sector
Subsector
Location
count Of Investments
count Of Exists
People
Employee Profiles2
Activity
Recent News5
The graph reveals the ratio (%) of positive news articles in a chosen time range